 "Divi's Labs surges 6% on successful USFDA inspection of Unit-2")
Divi’s Laboratories has moved higher by 6% to Rs 915 on BSE in intra-day trade after the company announced that all the previous observations by US drug regulator regarding Unit-2 of its Visakhapatnam facility have been confirmed as completed and resolved.
The stock hit nine-month high and was trading at its highest level since December 23, 2016 on BSE. It outperformed the market by surging 47% in past one month, as compared to 4% rise in the S&P BSE Sensex.
“Unit-2 has been inspected by the U.S. Food and Drug Administration (US-FDA) from September 11 to September 19, 2017. This inspection was for full cGMP and verification of all corrective actions proposed against the previous Inspection observations,” Divi’s Laboratories said in a BSE filing.
The company announced that all previous observations have been confirmed as completed and resolved, it added.
On completion of this inspection, Divi's Laboratories has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time.
At 10:47 AM; the stock was up 5% at Rs 908 on BSE, as compared to a marginal 0.03% rise in the Sensex. A combined 7.47 million shares changed hands on the counter on BSE and NSE so far.
The stock hit nine-month high and was trading at its highest level since December 23, 2016 on BSE. It outperformed the market by surging 47% in past one month, as compared to 4% rise in the S&P BSE Sensex.
“Unit-2 has been inspected by the U.S. Food and Drug Administration (US-FDA) from September 11 to September 19, 2017. This inspection was for full cGMP and verification of all corrective actions proposed against the previous Inspection observations,” Divi’s Laboratories said in a BSE filing.
The company announced that all previous observations have been confirmed as completed and resolved, it added.
On completion of this inspection, Divi's Laboratories has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time.
At 10:47 AM; the stock was up 5% at Rs 908 on BSE, as compared to a marginal 0.03% rise in the Sensex. A combined 7.47 million shares changed hands on the counter on BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%